A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors.

Autor:	Stella, Manuela, Biassoni, Erica, Fiorillo, Chiara, Grandis, Marina, Mattioli, Francesca, Del Sette, Massimo
Předmět:	MUSCLE diseases MUSCLE weakness GLUCOSE SODIUM-glucose cotransporter 2 inhibitors DRUG dosage POSTPOLIOMYELITIS syndrome
Zdroj:	Neurological Sciences; Jul2022, Vol. 43 Issue 7, p4567-4570, 4p, 1 Color Photograph, 1 Black and White Photograph
Abstrakt:	Inflammatory myopathies, including immune-mediated necrotizing myopathy (IMNM), are a rare and heterogeneous group of autoimmune diseases which can even involve extramuscular districts and seriously impact patients' quality of life. We report the case of a 76-year-old woman who developed muscle weakness, fatigue, and increased CK, following treatment with dapagliflozin, a sodium/glucose co-transporter 2 (SGLT2) inhibitor, and metformin. Neurophysiology, muscle biopsy, and antibody dosage confirmed the diagnosis of IMNM. The temporal correlation between the onset of clinical manifestations and the increase in the dosage of antidiabetic drugs, the improvement of symptoms with the dechallenge of dapagliflozin, and the exclusion of other possible causes triggering myopathy suggests that this may be the first case of dapagliflozin-induced myopathy, different from the former one associated with the use of SGLT2 inhibitors. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.